GSE123905 adenosine 1 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE123905_adenosine_1_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE123905_adenosine_1_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE123905_adenosine_1_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE123905_adenosine_1_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

S100 calcium binding protein P

Gene

argininosuccinate synthase 1

Gene

activated leukocyte cell adhesion molecule

Gene

ChaC glutathione specific gamma-glutamylcyclotransferase 1

Gene

G0/G1 switch 2

Gene

15-hydroxyprostaglandin dehydrogenase

Gene

solute carrier family 38 member 1

Gene

galectin 3 binding protein

Gene

plasminogen activator, tissue type

Gene

asparagine synthetase (glutamine-hydrolyzing)

  • Gene

    S100 calcium binding protein P


  • Gene

    argininosuccinate synthase 1


  • Gene

    activated leukocyte cell adhesion molecule


  • Gene

    ChaC glutathione specific gamma-glutamylcyclotransferase 1



  • Gene

    15-hydroxyprostaglandin dehydrogenase


  • Gene

    solute carrier family 38 member 1


  • Gene

    galectin 3 binding protein


  • Gene

    plasminogen activator, tissue type


  • Gene

    asparagine synthetase (glutamine-hydrolyzing)

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.